Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic dru...

Description complète

Détails bibliographiques

Auteurs principaux:	Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2026-04-01
Collection:	Annals of Clinical and Translational Neurology
Sujets:	complement inhibition complement pathway eculizumab myasthenia gravis ravulizumab
Accès en ligne:	https://doi.org/10.1002/acn3.70251
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!